Year 2018 / Volume 110 / Number 7
Original
Long-term results of linaclotide in the treatment of constipation-type irritable bowel syndrome

451-457

DOI: 10.17235/reed.2018.5268/2017

Fernando Geijo Martínez, Ana Sánchez Garrido, Héctor Marcos Prieto, Concepción Piñeiro Pérez, Ana Beatriz Prieto Bermejo, Alberto Álvarez Delgado, Antonio Velasco Guardado, Antonio Rodríguez Pérez,

Abstract
Background: constipation-predominant irritable bowel syndrome (C-IBS) is a prevalent, complex and multifactorial disorder that represents a challenge in terms of diagnosis and therapeutic management. Objective: to evaluate the effectiveness, safety and treatment satisfaction of linaclotide in C-IBS patients. Methods: prospective, single-center and observational study conducted in patients diagnosed with C-IBS. The patients were treated with linaclotide (Constella®, Allergan Inc., Irvine, CA), once-daily via an oral capsule of 290-μg, 30 minutes before breakfast. The primary effectiveness endpoint was the number of bowel movements per week. The secondary endpoints included treatment satisfaction and changes from baseline in frequency and severity of symptoms (abdominal pain and bloating). This was assessed via an 11-point visual analog scale (VAS) reported by the patients in a daily register. Results: thirty female patients were consecutively included. The median follow-up time was 18 months. The mean (standard deviation [SD]) number of weekly bowel movements significantly increased from 0.9 (0.6) at baseline to 4.7 (3.9) at the end of follow-up, p < 0.0001. Abdominal pain significantly decreased from 5.7 (2.3) at baseline to 3.1 (2.8) at the end of the follow-up period, p < 0.0001. Similarly, bloating significantly decreased from 6.8 (1.6) to 2.9 (2.5) at the beginning and end of the treatment period, respectively, p < 0.0001. The mean (SD) degree of satisfaction at the end of the study was 6.7 (3.0). Conclusions: long-term linaclotide treatment in patients with C-IBS is effective and safe in the clinical setting.
Share Button
New comment
Comments
No comments for this article
References
1. Quigley EM, Abdel-Hamid H, Barbara G, Bhatia SJ, Boeckxstaens G, De Giorgio R, et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol. 2012 May-Jun;46(5):356-66.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4.
3. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014 Aug;109 Suppl 1:S2-26; quiz S27.
4. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al; Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007 Dec;56(12):1770-98. Erratum in: Gut. 2008 Dec;57(12):1743.
5. Rey E, Balboa A, Mearin F. Chronic constipation, irritable bowel syndrome with constipation and constipation with pain/discomfort: similarities and differences. Am J Gastroenterol. 2014 Jun;109(6):876-84.
6. Tillisch K, Labus JS, Naliboff BD, Bolus R, Shetzline M, Mayer EA, et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol. 2005 Apr;100(4):896-904.
7. Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel
Disorders. Gastroenterology. 2016 Feb 18. pii: S0016-5085(16)00222-5.
8. Saha, L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J. Gastroenterol. 2014, 20, 6759–6773.
9. Rey Díaz-Rubio E, Mascort Roca JJ, Peña Forcada E, Cañones Garzón P, Tenias Burillo JM, Júdez Gutiérrez FJ. Management of the clinical issue of constipation with abdominal complaints in adults. A national survey of Primary Care physicians and gastroenterologists. Rev Esp Enferm Dig. 2016 Jun;108(6):323-31.
10. Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, et al. Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016 Jun;108(6):332-63.
11. Rey E, Mearin F, Alcedo J, Ciriza C, Delgado-Aros S, Freitas T, et al. Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report. Adv Ther. 2017 Mar;34(3):587-598.
12. Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther. 2011 Apr;130(1):71-82.
13. Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010 Dec 15;649(1-3):328-35.
14. Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil. 2010 Mar;22(3):312-e84.
15. Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. Gastroenterology. 2013 Dec;145(6):1334-46.e1-11.
16. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012 Nov;107(11):1714-24; quiz p.1725.
17. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012 Nov;107(11):1702-12.
18. Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther. 2013 Jan;37(1):49-61.
19. Macdougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, et al. An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil. 2013 Jun;25(6):481-6.
20. Tse Y, Armstrong D, Andrews CN, Bitton A, Bressler B, Marshall J, et al.Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents. Can J Gastroenterol Hepatol. 2017; 2017:8612189.
21. Lacy BE, Lembo AJ, Macdougall JE, Shiff SJ, Kurtz CB, Currie MG, et al.
Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C. Neurogastroenterol Motil. 2014 Mar;26(3):326-33.
22. Andresen V, Diemert S, Miehlke S, Beck E, Prechtl A, Layer P. Effectiveness and tolerability of linaclotide in the treatment of ibs-c in a real-world setting: results from a german non-interventional study. Disponible en https://uegw.congress-online.com/guest/IDe74b14611d0e7e/AbstractView?ABSID=10829 Último acceso 05 de junio 2017.
23. Shearer J, Paine P, Rej A, Agrawal A, Ford AC. Efficacy of Linaclotide in Constipation-Predominant Irritable Bowel Syndrome in Routine Clinical Practice: A Multicentre Experience. Gastroenterology. 2016; 150 (4): S737-S738.
24. Serrano B, Delgado-Aros S, Mearin F, Ciriza de los Ríos C,
Serra J, Mínguez Pérez M, et al. Respuesta de los síntomas intestinales,
No intestinales y extradigestivos a linaclotida en pacientes con síndrome del intestino irritable con estreñimiento: la respuesta a las 4 semanas de tratamiento predice la respuesta mantenida [P 209]. Gastroenterol Hepatol. 2017;40(3):166.
25. Mínguez Cortes JM. Evaluación de tratamiento con linaclotida en un hospital comarcal. P40. Disponible en https://www.sapd.es/revista/article.php?file=vol38_n5_reunion/25 Último acceso 26 de mayo 2017.
26. Lachin JM. Fallacies of last observation carried forward analyses. Clin Trials. 2016 Apr;13(2):161-8.
Related articles

Letter

An unusual cause of abdominal pain in an older female

DOI: 10.17235/reed.2023.9898/2023

Letter

Isolated Jejunal Crohn's Disease: a challenging diagnosis

DOI: 10.17235/reed.2022.9423/2022

Letter

Median arcuate ligament syndrome: a rare cause of abdominal pain

DOI: 10.17235/reed.2023.9404/2022

Digestive Diseases Image

A surprising white thread on a terminal ileoscopy

DOI: 10.17235/reed.2022.9311/2022

Letter

Subacute distal ileitis in a healthy young adult

DOI: 10.17235/reed.2021.7831/2021

Digestive Diseases Image

Celiac trunk segmental arterial mediolysis: a rare cause of arteriopathy

DOI: 10.17235/reed.2020.7143/2020

Letter

Chronic abdominal pain due to mesenteric schwannoma

DOI: 10.17235/reed.2020.6876/2020

Digestive Diseases Image

An unusual association: median arcuate ligament syndrome and nutcracker syndrome

DOI: 10.17235/reed.2019.5997/2018

Special Article

Consensus document on exclusion diets in irritable bowel syndrome (IBS)

DOI: 10.17235/reed.2018.5941/2018

Case Report

Cannabis intake and intussusception: an accidental association?

DOI: 10.17235/reed.2016.4288/2016

Letter to the Editor

An unusual etiology of abdominal pain in children

DOI: 10.17235/reed.2016.4168/2015

Letter to the Editor

Unusual course of epiploic appendicitis

DOI: 10.17235/reed.2015.3796/2015

Citation tools
Geijo Martínez F, Sánchez Garrido A, Marcos Prieto H, Piñeiro Pérez C, Prieto Bermejo A, Álvarez Delgado A, et all. Long-term results of linaclotide in the treatment of constipation-type irritable bowel syndrome . 5268/2017


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1111 visits.
This article has been downloaded 357 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 19/09/2017

Accepted: 11/02/2018

Online First: 24/04/2018

Published: 02/07/2018

Article revision time: 110 days

Article Online First time: 217 days

Article editing time: 286 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology